Statement of Changes in Beneficial Ownership (4)
10 Octobre 2019 - 11:41PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
JOHNSON RADY A |
2. Issuer Name and Ticker or Trading Symbol
PFIZER INC
[
PFE
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Executive Vice President
|
(Last)
(First)
(Middle)
PFIZER INC.-CORP. SECRETARY, 235 EAST 42ND ST. |
3. Date of Earliest Transaction
(MM/DD/YYYY)
10/9/2019
|
(Street)
NEW YORK, NY 10017
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code (Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)
|
8. Price of Derivative Security (Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Phantom Stock Units SSP
|
(1)
|
10/9/2019
|
|
A
|
|
19.0000
|
|
(2)
|
(2)
|
Common Stock
|
19.0000
|
$35.6900
|
5014.0000
|
D
|
|
Explanation of Responses:
|
(1)
|
Each unit represents one phantom share of common stock.
|
(2)
|
These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
JOHNSON RADY A PFIZER INC.-CORP. SECRETARY 235 EAST 42ND ST. NEW YORK, NY 10017
|
|
|
Executive Vice President
|
|
Signatures
|
Susan E. Grant, by power of atty., for Rady A. Johnson
|
|
10/10/2019
|
**Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person, see Instruction 4(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Pfizer (NYSE:PFE)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Pfizer (NYSE:PFE)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024
Coca-Cola and Microsoft Sign Billion-Dollar Agreement, Apple Event Set for May 7, and More News Mercredi 24 Avril 2024 ( il y a 8 heures) • IH Market News |
European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options Lundi 22 Avril 2024 ( il y a 2 jours) • Business Wire |
Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25 Jeudi 11 Avril 2024 ( il y a 2 semaines) • Business Wire |
Delta Generates US$37 Million Profit in Q1, Google and Intel Unveil Cutting-Edge AI Chips, and More News Mercredi 10 Avril 2024 ( il y a 2 semaines) • IH Market News |
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease Mardi 9 Avril 2024 ( il y a 2 semaines) • Business Wire |
ALTIVIA Appoints Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering Manager Lundi 8 Avril 2024 ( il y a 2 semaines) • PR Newswire (US) |
Super Micro Computer and Seagate Shares Surge on Analyst Optimism in Pre-Market Trading, and Latest News Mardi 26 Mars 2024 ( il y a 4 semaines) • IH Market News |
Apple Pre-Market Drop Due to Antitrust Threats, Surprising Profit Boosts Micron Shares, and Latest Market Updates Jeudi 21 Mars 2024 ( il y a 1 mois) • IH Market News |
Pfizer Invites Public to View and Listen to Webcast of May 1 Conference Call with Analysts Mercredi 20 Mars 2024 ( il y a 1 mois) • Business Wire |
Unilever Initiates Ice Cream Division Spin-Off and Announces Job Cuts; Berkshire Ramps Up Share Buyback Efforts, and More Mardi 19 Mars 2024 ( il y a 1 mois) • IH Market News |
Apple & Google in Talks for Gemini AI on iPhone, Nvidia’s GTC Conference Today, and Latest News Lundi 18 Mars 2024 ( il y a 1 mois) • IH Market News |
European Commission Approves Pfizer’s PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease Mercredi 13 Mars 2024 ( il y a 1 mois) • Business Wire |
Plus d'articles sur Pfizer Inc
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.